SCHEDULE 13G/A 0001940272 XXXXXXXX LIVE 2 Common Stock, $0.00001 par value per share 06/30/2025 0001279704 Cellectar Biosciences, Inc. 15117F500 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 2962.00 0.00 2962.00 2962.00 N 0.1 IA OO Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP and (ii) 422 Shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering). ADAR1 Capital Management GP, LLC b TX 0.00 2540.00 0.00 2540.00 2540.00 N 0.1 OO Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP as of June 30, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering). Daniel Schneeberger b V8 0.00 2962.00 0.00 2962.00 2962.00 N 0.1 HC IN Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP and (ii) 422 Shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering). ADAR1 Partners, LP b DE 0.00 0.00 0.00 0.00 0.00 N 0 PN Cellectar Biosciences, Inc. 100 CAMPUS DRIVE FLORHAM PARK, NJ, 07932 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); (iii) Daniel Schneeberger ("Mr. Schneeberger"); and (iv) ADAR1 Partners, LP. The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; (iii) Mr. Schneeberger is a citizen of Switzerland; and (iv) ADAR1 Partners LP, is a Delaware limited partnership. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. N Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 08/14/2025 ADAR1 Capital Management GP, LLC /s/ Daniel Schneeberger 08/14/2025 Daniel Schneeberger /s/ Daniel Schneeberger 08/14/2025 ADAR1 Partners, LP /s/ Daniel Schneeberger 08/14/2025